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Background: Constipation is a frequent complaint and the combination of a prebiotic and probiotics could have a
potentially synergic effect on the intestinal transit. The present study therefore aims to investigate the combination
of polydextrose (Litesse®), L. acidophilus NCFM® and B. lactis HN019 in a yogurt on intestinal transit in subjects who
suffer from constipation.
Methods: Patients with constipation were randomly divided into two groups, Control Group (CG) and Treatment
Group (TG), and had to eat 180 ml of unflavored yogurt every morning for 14 days. Those in the CG received only
yogurt, while the TG received yogurt containing polydextrose, L. acidophilus NCFM® (ATCC 700396) and B. lactis
HN019 (AGAL NM97/09513).
Results: Favourable clinical response was assessed since Agachan score had a significant reduction at the end
of the study in both groups and tended to be better in the TG. The subjects in the treatment group also had a
shorter transit time at the end of the intervention compared to the control group (p = 0.01).
Conclusion: The product containing yogurt with polydextrose, B. lactis HN019 and L. acidophilus NCFM® significantly
shortened colonic transit time after two weeks in the TG compared to CG and may be an option for treatment of
constipation.
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Constipation is a frequent complaint and corresponds to
various symptoms such as irregular voiding, sensation of
incomplete, painful or forceful voiding, hard stools and ab-
dominal discomfort. Incorrect diet can, in part, explain in-
testinal motility disorders or dyssynergic defecation [1].
The increase in the incidence of intestinal function
disturbances is especially present in developed countries,
since the industrialization of food provides access to prod-
ucts of greater conservation, which is accompanied by a* Correspondence: danimagro@terra.com.br
1Department of Surgery, Faculty of Medical Sciences, Campinas State
University, Campinas, Brazil
Full list of author information is available at the end of the article
© 2014 Magro et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.reduction of fiber content [2]. Furthermore, the population
has adopted a sedentary life style, which is associated with
an inadequate diet and results in constipation.
Increased consumption of foods rich in fiber, such as,
vegetables, fruit, and whole grain products, make up the
primary treatment for constipation, besides the recom-
mendation of an adequate ingestion of liquid (basically
water) and the practice of physical activity [3]. Studies
have shown that food high in fibers, such as, resistant
starch, pectin (fruit) and (hemi) cellulose (grains and ce-
reals) promote an improvement of intestinal peristalsis
and an increase in fecal weight, all acting as natural laxa-
tive [4]. Polydextrose is a polysaccharide that is partially
fermented in the large intestine, but is not digested orLtd. This is an Open Access article distributed under the terms of the Creative
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it is excreted in the stool. It presents the same properties
of fibers and promotes a shorter time passing through
the intestines and improves the consistency of the stool
[5,6]. It also acts as a substrate for beneficial endogenous
microbes, allowing an increase in their levels and activity
in the intestinal lumen [7,8].
Probiotics have been defined as live microorganisms
which when administered in adequate amounts confer a
health benefit on the host [9]. They should be viable in
the conditions of the gastric lumen and have the capabil-
ity to adhere to the intestinal epithelium [10]. Selected
probiotic strains have been reported to aid in the pre-
vention and treatment of diarrhea caused by rotavirus
and/or antibiotic therapy, reduction in the concentration
of enzymes which promote cancer, prevention and/or re-
lief of allergic symptoms in children, normalization of
bowel movements and stool consistency in individuals
who are constipated [11].
To obtain these benefits, as a rule of thumb a dose of
at least a billion colony forming units should be con-
sumed daily. A probiotic preparation can consist of a
single strain or a combination of strains and can be in
association with other biologically active ingredients.
Probiotics are often included in dairy products [12],
since these foods provide a preferred growth medium
for many of these microorganisms.
Currently, there is great interest in functional foods.
There are, however, few studies that evaluate their effect
on constipation. The use of probiotics hold great prom-
ise, and, among the microorganisms evaluated most are
of Bifidobacterium and Lactobacillus. Two randomized
studies using products containing Bifidobacterium lactis
DN-173 010 showed a significant increase in the fre-
quency of evacuation when compared to the control
group [13,14]. Also B. lactis HN019 has been shown, in
a dose depended manner, to shorten intestinal transit in
subjects with self reported long transit times [15].
Using Lactobacillus casei Shirota, Koebenick et al. [16]
demonstrated an improvement of the symptoms associ-
ated with constipation in comparison to placebo. How-
ever, the results when using probiotics with children
who are suffering from constipation are inconsistent.
Bu et al. [17], showed that the use of Lactobacillus
rhamnosus Lce35 increased evacuation frequency, however,
there was no difference when compared to children who
took oral laxatives. Two other studies [18,19] showed no
evidence of improvement with constipated children using
probiotics.
The combination of a prebiotic and probiotics would
have a potentially synergic effect on the intestinal
transit, as has been shown [20]. The present study
therefore aimed to investigate the combination of poly-
dextrose L. acidophilus NCFM® and B. lactis HN019 ina yogurt on intestinal transit in subjects who suffer
from constipation.Methods
Patients
Volunteers were recruited among subjects with chronic
constipation. Subjects were of both genders, and between
the ages of 18–45 years. In order to evaluate the degree of
constipation, the Agachan score [21] and colonic transit
time were used. The inclusion Agachan score was from 10
to 20. Subjects with hypothyroidism, antidepressant users,
normal colonic transit time (CTT; 24 h or less) as well as
higher than 96 hours were excluded.
The subjects recruited were allocated randomly (per-
muted-block randomization) within two groups, Control
Group (CG) and Treatment Group (TG) and consumed
180 ml of unflavored yogurt every morning for 14 days.
Those in the CG received only yogurt, while the TG re-
ceived yogurt containing polydextrose, L. acidophilus
NCFM® (ATCC 700396) and B. lactis HN019 (AGAL
NM97/09513). The clinical evaluations for the Agachan
score and the colon transit time were done immediately
before the beginning of the experiment and at the end.
The patients received a card for making daily entries of
evacuations and were warned not to take any laxatives, fiber
supplements, neither yogurt nor fermented milk. Comple-
mentary evaluations were made: body mass index (BMI),
food profile/diet, and the recommended liquid con-
sumption of each participant. The local ethical commit-
tee approved the project (N°. 454/2008). Registered
under ClinicalTrials.gov identifier no. NCT01825434.Yogurt preparation
Unflavored yogurt was prepared on one occasion for the
whole experiment. For the TG, 3.6 g of polydextrose (in
the form of 4 grams of Litesse®, Danisco Brazil, Cotia) L.
acidophilus NCFM® and B. lactis HN019 (Danisco Brazil,
Cotia) were included in the yogurt with, at least 109 colony
forming units (CFU) per strain per portion. All test prod-
ucts were packaged, labeled and randomized before the
study. The study was blinded to investigators and volun-
teers and the code was secured in a sealed envelope. The
presentation was identical as to the consistency, taste, odor,
and appearance.Protocol of colic transit study
The patients took one capsule a day which contained 24
markers (Sitzmarks©) with three different formats for
three consecutive days and had an abdominal x-ray the
day after ingesting the third capsule. An evaluation with
the total of markers was made before; day 0 and at the
end of the study; day 14th day, of eating yogurt.
Table 1 Baseline characteristics of treatment vs control
groups
CG TG p-value
Female 19 (90.5%) 24 (92.3%) 1.0000**
Male 2 (9.5%) 2 (7.7%)
Age (years) 32.7 ± 7.3 31.5 ± 7.1 0.5773*
BMI (kg/m2) 26.8 ± 4.8 28.2 ± 5.9 0.4475*
BM (/week) 7.4 ± 3.5 6.8 ± 2.6 0.9175*
Use of laxatives 4 (19.1%) 6(23.1%) 1.0000**
*Mann-Whitney, **Fisher test.
Table 3 Bowel movements/day (mean, standard deviation)
Group N. Initial Final
CG 21 0.7, 0.3* 0.7, 0.3*
TG 26 0.7, 0.3* 0.8, 0.3*
CG control Group, TG treatment group.
Comparison of data with the same symbol; * p > 0.05.
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Fisher’s exact test, Mann-Whitney U test and t-test were
used for the statistical analyses when appropriate. The
level of significance was considered at 5%.Results
The number of patients assessed was 71 and 24 of them
were excluded due to: normal CTT (12); Changed mind
on participation (10); inadequate tolerance to yogurt (2);
and there were no exclusions due to collateral effects. Of
the 47 individuals who participated 43 (91.5%) were
women. The Control Group (CG) had 21 participants
while the Treatment Group (TG) had 26. No significant
statistical differences were observed as to gender, age,
BMI, frequency of bowel movements per week (BM) and
use of laxatives between the two groups (Table 1).
Samples of the yogurt were analyzed at the end of the
study to quantify the amount of polydextrose as well the
probiotic content. The amount of polydextrose was not
changed at the end of the study (14 days) and the levels
of B. lactis and L. acidophilus were more than 1×109
CFU/portion for each strain.
Favourable clinical response was assessed since Agachan
score had a significant reduction at the end of the
study in both groups and tended to be better in the TG
(Table 2). The number of bowel movements per day
remained unchanged for the duration of the study
(Table 3).
The subjects in the treatment group also had a shorter
transit time at the end of the intervention compared to
the control group (t-test, p = 0.01), Table 4.Table 2 Initial and final Agachan´s score per group
(mean, standard deviation)
Group N. Initial Final
CG 21 14.3 ± 2.4*§ 8.3 ± 3.5§★
TG 26 13.8 ± 2.1*✗ 5.3 ± 2.9✗★
CG control Group, TG treatment group.
Comparison of data with the same symbol; *p > 0.05, §p < 0.001, ✗p < 0.001,
★p = 0.005.Discussion
Despite constipation being a frequent complaint in spe-
cialized clinics, fortunately, only a few of the cases are
considered grave by having long periods without evacu-
ating or not responding to the use of laxatives. These
are difficult to deal with, making it necessary to perform
specific exams, such as, defecography or CTT. In the
majority of the cases, the patients present problems as-
sociated with bad dietary habits and sedentary life style.
In this situation, dietary advice and more frequent use of
fibers and sufficient intake of liquids, make it a manage-
able condition [22], nevertheless with varied results,
hence the necessity to search for more efficient treat-
ments. Functional foods could be promising in alleviat-
ing motility problems of the gastrointestinal tract, in
relation to irritable bowel syndrome and constipation
[23]. Besides this, there is data showing that the intes-
tinal microbiota is diverse among healthy individuals
and sufferers of constipation [24,25]. In such case, inter-
vention with probiotics could be accompanied by modi-
fication of intestinal transit time as observed by Marteau
et al. [26]. The decrease of the intestinal pH [27], a com-
petitive action with intestinal pathogen(s) or production
of substances with neurotransmitter activities [28] are
some of the mechanisms attributed to selected strains of
probiotics which stimulate the intestinal peristalsis.
In the present study, a reduction of CTT using radio
opaque pellets was observed. This reduction was only
significant for the Treatment Group and was also signifi-
cantly different from the final CTT of the Control
Group. Although the main inclusion criterion was slow
intestinal transit, some volunteers exhibited a normal
transit time of around 24 h. Despite this, a significant
reduction in transit time was observed for the whole
Treatment Group. However, subjects with a close to
normal transit time were not suffering from unnecessary
further shortening and potential diarrhea. Despite this
difference in transit time between the groups, the Aga-
chan score improved in both test groups and was not
different between the groups. The used B. lactis strain,Table 4 Colonic transit time (hours) as evaluated by
abdominal X-ray of consumed radio-opaque markers
Group N. Initial Final
CG 21 37.8 ± 15.2 33.9 ± 12.4§
TG 26 35.0 ± 15.4* 24.6 ± 12.8*§
Comparison of data with the same symbol; *p = 0.001, §p = 0.01.
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transit in a placebo controlled dose ranging study [15,29].
The present study confirms these observations. Also other
probiotics have been reported to shorten colonic transit;
Yang et al. [13] saw that the use of B. lactis DN-173 010 for
periods of over two weeks was accompanied by an increase
in the frequency of bowel movements in women who
suffered from constipation. A study by Guyonet and co-
workers [14] showed an improvement in bowel function in
constipated subjects with Irritable Bowel Syndrome after
the use of the same B. lactis for six weeks. In a similar man-
ner, Koebnick et al. [16] verified that the use of L. acidoph-
ilus Shirota was accompanied by an improvement of the
symptoms related to constipation.
The third biologically active component in the test
yogurt; polydextrose has also been reported to positively
influence stool consistency and bowel function [30]
Likewise, Hengst et al. [6] reported that a yogurt con-
taining polydextrose reduced oro-faecal transit time, as
well as an improvement in the fecal consistency.
Conclusions
The product containing yogurt with polydextrose, B. lac-
tis HN019 and L. acidophilus NCFM® significantly short-
ened colonic transit time after two weeks and may be an
option for treatment of constipation.
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